Aaron N. Smith, In-Young Choi, Phil Lee, Debra K. Sullivan, Jeffrey M. Burns, Russell H. Swerdlow, Emma Kelly, Matthew K. Taylor
{"title":"一水肌酸在阿尔茨海默病中的试验：可行性、脑肌酸和认知","authors":"Aaron N. Smith, In-Young Choi, Phil Lee, Debra K. Sullivan, Jeffrey M. Burns, Russell H. Swerdlow, Emma Kelly, Matthew K. Taylor","doi":"10.1002/trc2.70101","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> BACKGROUND</h3>\n \n <p>Preclinical studies suggest that creatine monohydrate (CrM) improves cognition and Alzheimer's disease (AD) biomarkers. However, there is currently no clinical evidence demonstrating the effects of CrM in patients with AD.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>In this single-arm pilot trial, we investigated the feasibility of 20 g/day CrM for 8 weeks in 20 patients with AD. We measured compliance throughout; serum creatine at baseline, 4 weeks, and 8 weeks; and brain total creatine (tCr) and cognition (National Institutes of Health [NIH] Toolbox, Mini-Mental State Examination [MMSE]) at baseline and 8 weeks.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>Nineteen participants achieved the target of ≥80% compliance with the CrM intervention. Serum Cr was elevated at 4 and 8 weeks (<i>p</i> < .001) and brain tCr increased by 11% (<i>p</i> < .001). Cognition improved on global (<i>p</i> = .02) and fluid (<i>p</i> = .004) composites, List Sorting (<i>p</i> = .001), Oral Reading (<i>p</i> < .001), and Flanker (<i>p</i> = .05) tests.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>Our data suggest that CrM supplementation is feasible in AD and provides preliminary evidence for future efficacy and mechanism studies.</p>\n </section>\n \n <section>\n \n <h3> Trial Registration</h3>\n \n <p>ClinicalTrials.gov, NCT05383833, registered on May 20, 2022.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Creatine monohydrate supplementation was feasible in patients with Alzheimer's disease.</li>\n \n <li>Creatine monohydrate was associated with increased brain total creatine.</li>\n \n <li>Creatine monohydrate was associated with improvements in cognition.</li>\n \n <li>Efficacy of creatine monohydrate in Alzheimer's disease should be studied further.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"11 2","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-05-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70101","citationCount":"0","resultStr":"{\"title\":\"Creatine monohydrate pilot in Alzheimer's: Feasibility, brain creatine, and cognition\",\"authors\":\"Aaron N. Smith, In-Young Choi, Phil Lee, Debra K. Sullivan, Jeffrey M. Burns, Russell H. Swerdlow, Emma Kelly, Matthew K. Taylor\",\"doi\":\"10.1002/trc2.70101\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div>\\n \\n \\n <section>\\n \\n <h3> BACKGROUND</h3>\\n \\n <p>Preclinical studies suggest that creatine monohydrate (CrM) improves cognition and Alzheimer's disease (AD) biomarkers. However, there is currently no clinical evidence demonstrating the effects of CrM in patients with AD.</p>\\n </section>\\n \\n <section>\\n \\n <h3> METHODS</h3>\\n \\n <p>In this single-arm pilot trial, we investigated the feasibility of 20 g/day CrM for 8 weeks in 20 patients with AD. We measured compliance throughout; serum creatine at baseline, 4 weeks, and 8 weeks; and brain total creatine (tCr) and cognition (National Institutes of Health [NIH] Toolbox, Mini-Mental State Examination [MMSE]) at baseline and 8 weeks.</p>\\n </section>\\n \\n <section>\\n \\n <h3> RESULTS</h3>\\n \\n <p>Nineteen participants achieved the target of ≥80% compliance with the CrM intervention. Serum Cr was elevated at 4 and 8 weeks (<i>p</i> < .001) and brain tCr increased by 11% (<i>p</i> < .001). Cognition improved on global (<i>p</i> = .02) and fluid (<i>p</i> = .004) composites, List Sorting (<i>p</i> = .001), Oral Reading (<i>p</i> < .001), and Flanker (<i>p</i> = .05) tests.</p>\\n </section>\\n \\n <section>\\n \\n <h3> DISCUSSION</h3>\\n \\n <p>Our data suggest that CrM supplementation is feasible in AD and provides preliminary evidence for future efficacy and mechanism studies.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Trial Registration</h3>\\n \\n <p>ClinicalTrials.gov, NCT05383833, registered on May 20, 2022.</p>\\n </section>\\n \\n <section>\\n \\n <h3> Highlights</h3>\\n \\n <div>\\n <ul>\\n \\n <li>Creatine monohydrate supplementation was feasible in patients with Alzheimer's disease.</li>\\n \\n <li>Creatine monohydrate was associated with increased brain total creatine.</li>\\n \\n <li>Creatine monohydrate was associated with improvements in cognition.</li>\\n \\n <li>Efficacy of creatine monohydrate in Alzheimer's disease should be studied further.</li>\\n </ul>\\n </div>\\n </section>\\n </div>\",\"PeriodicalId\":53225,\"journal\":{\"name\":\"Alzheimer''s and Dementia: Translational Research and Clinical Interventions\",\"volume\":\"11 2\",\"pages\":\"\"},\"PeriodicalIF\":6.8000,\"publicationDate\":\"2025-05-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70101\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Alzheimer''s and Dementia: Translational Research and Clinical Interventions\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/trc2.70101\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/trc2.70101","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
Creatine monohydrate pilot in Alzheimer's: Feasibility, brain creatine, and cognition
BACKGROUND
Preclinical studies suggest that creatine monohydrate (CrM) improves cognition and Alzheimer's disease (AD) biomarkers. However, there is currently no clinical evidence demonstrating the effects of CrM in patients with AD.
METHODS
In this single-arm pilot trial, we investigated the feasibility of 20 g/day CrM for 8 weeks in 20 patients with AD. We measured compliance throughout; serum creatine at baseline, 4 weeks, and 8 weeks; and brain total creatine (tCr) and cognition (National Institutes of Health [NIH] Toolbox, Mini-Mental State Examination [MMSE]) at baseline and 8 weeks.
RESULTS
Nineteen participants achieved the target of ≥80% compliance with the CrM intervention. Serum Cr was elevated at 4 and 8 weeks (p < .001) and brain tCr increased by 11% (p < .001). Cognition improved on global (p = .02) and fluid (p = .004) composites, List Sorting (p = .001), Oral Reading (p < .001), and Flanker (p = .05) tests.
DISCUSSION
Our data suggest that CrM supplementation is feasible in AD and provides preliminary evidence for future efficacy and mechanism studies.
Trial Registration
ClinicalTrials.gov, NCT05383833, registered on May 20, 2022.
Highlights
Creatine monohydrate supplementation was feasible in patients with Alzheimer's disease.
Creatine monohydrate was associated with increased brain total creatine.
Creatine monohydrate was associated with improvements in cognition.
Efficacy of creatine monohydrate in Alzheimer's disease should be studied further.
期刊介绍：
Alzheimer''s & Dementia: Translational Research & Clinical Interventions (TRCI) is a peer-reviewed, open access,journal from the Alzheimer''s Association®. The journal seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer''s disease. The journal will publish findings from diverse domains of research and disciplines to accelerate the conversion of abstract facts into practical knowledge: specifically, to translate what is learned at the bench into bedside applications. The journal seeks to publish articles that go beyond a singular emphasis on either basic drug discovery research or clinical research. Rather, an important theme of articles will be the linkages between and among the various discrete steps in the complex continuum of therapy development. For rapid communication among a multidisciplinary research audience involving the range of therapeutic interventions, TRCI will consider only original contributions that include feature length research articles, systematic reviews, meta-analyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that would advance wide range of interventions to ameliorate symptoms or alter the progression of chronic neurocognitive disorders such as dementia and Alzheimer''s disease. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurophysiology, neurology, psychiatry, clinical psychology, bioinformatics, pharmaco-genetics, regulatory issues, health economics, pharmacoeconomics, and public health policy as these apply to preclinical and clinical research on therapeutics.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
